BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...Phase I testing designed to secrete an OX40 ligand...
...anti-ILT4 mAb.Checkpoint ligands MICA, MICB, NCR1 and OX40L...
...are the most established, with programs against OX40L...
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

The shifting balance between oncology candidates and patients available for trials, and the rise of complex modalities, is shaping the way MD Anderson builds partnerships and develops new assets. University of Texas MD Anderson Cancer...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

...in potential milestones. While Kymab’s antibodies span various mechanisms, the company’s lead program targets co-stimulatory checkpoint OX40L...
BioCentury | Jan 12, 2021
Product Development

OX40L pipeline: Data Byte

...OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer. OX40L...
...an adenovirus engineered to express OX40L, while Sichuan Clover Biopharmaceuticals Inc. and Shattuck Labs Inc. (NASDAQ:STTK) are investigating OX40L...
...TAK-252 ISB 830 Kymab Group Ltd. Moderna Inc. Takeda Pharmaceutical Co. Ltd. AbbVie Inc. HiFiBiO Therapeutics DNAtrix Inc. Ichnos Sciences Shattuck Labs Inc. OX40 ligand (OX40L) (CD134L) Tumor...
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

...Pharma gains mAb pipeline, including OX40L, derived from mouse platform By Paul Bonanos, Associate Editor More...
...CD134L) - OX40 ligandPD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Paul Bonanos KY1005 Kymab Group Ltd. Sanofi OX40 ligand...
...OX40 ligandPD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Paul Bonanos KY1005 Kymab Group Ltd. Sanofi OX40 ligand (OX40L) (CD134L) bee2021...
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...require additional clinical studies, according to the company.Anti-OX40L mAb meets in dermatitis Phase II KY1005, an anti-OX40L...
...dermatitis. TARGETSANGPTL3 - Angiopoietin-like 3BCMA (TNFRSF17; CD269) – Tumor necrosis factor receptor superfamily member 17OX40L (CD134L) – OX40 ligand BC...
Items per page:
1 - 10 of 122